Ratings by Chardan (Andreas Argyrides)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/19/2026 | MannKind | MNKD | New Coverage | Buy (N/A) |
3.04 (3.20) |
5.26% | Details | |
| 10/13/2026 | Gossamer Bio Inc. | GOSS | New Coverage | Buy (N/A) |
9.31 (9.46) |
1.61% | Details | |
| 10/13/2026 | Inhibikase Therapeutics Inc | IKT | New Coverage | Neutral (N/A) |
1.97 (1.63) |
-17.26% | Details | |
| 9/18/2026 | Agenus Inc. | AGEN | New Coverage | Buy (N/A) |
7.22 (6.51) |
-9.83% | Details | |
| 8/18/2026 | EyePoint Inc. | EYPT | Downgrade | Neutral (Buy) |
4.87 (0.43) |
-91.17% | Details | |
| 8/18/2026 | Rani Therapeutics | RANI | New Coverage | Buy (N/A) |
0.80 (0.59) |
-26.25% | Details |
